JP2021169534A5 - - Google Patents

Download PDF

Info

Publication number
JP2021169534A5
JP2021169534A5 JP2021127278A JP2021127278A JP2021169534A5 JP 2021169534 A5 JP2021169534 A5 JP 2021169534A5 JP 2021127278 A JP2021127278 A JP 2021127278A JP 2021127278 A JP2021127278 A JP 2021127278A JP 2021169534 A5 JP2021169534 A5 JP 2021169534A5
Authority
JP
Japan
Prior art keywords
composition
administered
platin
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021127278A
Other languages
English (en)
Japanese (ja)
Other versions
JP7193591B2 (ja
JP2021169534A (ja
Filing date
Publication date
Priority claimed from JP2018555499A external-priority patent/JP6928000B2/ja
Application filed filed Critical
Publication of JP2021169534A publication Critical patent/JP2021169534A/ja
Publication of JP2021169534A5 publication Critical patent/JP2021169534A5/ja
Application granted granted Critical
Publication of JP7193591B2 publication Critical patent/JP7193591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021127278A 2016-04-22 2021-08-03 化学療法の改善 Active JP7193591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326144P 2016-04-22 2016-04-22
US62/326,144 2016-04-22
JP2018555499A JP6928000B2 (ja) 2016-04-22 2017-04-21 化学療法の改善

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018555499A Division JP6928000B2 (ja) 2016-04-22 2017-04-21 化学療法の改善

Publications (3)

Publication Number Publication Date
JP2021169534A JP2021169534A (ja) 2021-10-28
JP2021169534A5 true JP2021169534A5 (enExample) 2022-01-06
JP7193591B2 JP7193591B2 (ja) 2022-12-20

Family

ID=60115481

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555499A Expired - Fee Related JP6928000B2 (ja) 2016-04-22 2017-04-21 化学療法の改善
JP2021127278A Active JP7193591B2 (ja) 2016-04-22 2021-08-03 化学療法の改善

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018555499A Expired - Fee Related JP6928000B2 (ja) 2016-04-22 2017-04-21 化学療法の改善

Country Status (6)

Country Link
US (1) US20190117620A1 (enExample)
EP (2) EP4035667A1 (enExample)
JP (2) JP6928000B2 (enExample)
AU (2) AU2017254774B2 (enExample)
CA (1) CA3058505A1 (enExample)
WO (1) WO2017181242A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190282540A1 (en) * 2016-04-06 2019-09-19 Noxopharm Limited Targeted drug delivery
JP2019513826A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
US20190117620A1 (en) * 2016-04-22 2019-04-25 Noxopharm Limited Chemotherapy improvements
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
EP2436680B1 (en) * 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US20190117620A1 (en) 2016-04-22 2019-04-25 Noxopharm Limited Chemotherapy improvements

Similar Documents

Publication Publication Date Title
JP2021169534A5 (enExample)
JP2022022264A5 (enExample)
JP2023002662A5 (enExample)
JP5911929B2 (ja) 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
JP2017516802A5 (enExample)
JP2024133474A5 (enExample)
RU2016151303A (ru) Применение эрибулина в лечении рака
RU2012157805A (ru) Способы лечения рака мочевого пузыря
JP2014512356A5 (enExample)
JP2020517696A5 (enExample)
JP2020523354A5 (enExample)
JP2019513812A5 (enExample)
JP2023116697A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
AU2017205749B2 (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
JP2021169534A (ja) 化学療法の改善
RU2011151854A (ru) Новые терапевтические способы применения инекальцитола
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени
RU2015126505A (ru) Применение и способы лечения заболеваний и патологических состояний печени
JP2020520385A5 (enExample)
JP2011514356A5 (enExample)
AU2002251763B2 (en) Method for treating cancer
JP2005509663A5 (enExample)
JPWO2020037152A5 (enExample)
RU2007111685A (ru) Применение 9-оксоакридин-10-уксусной кислоты и/или ее соли в комбинации с антиэстрогеном и/или прогестином для лечения этрогензависимых опухолей, способ лечения и наборы